Published in final edited form as:

Gynecol Oncol. 2019 March ; 152(3): 587–593. doi:10.1016/j.ygyno.2018.12.013.

Variation in resource utilization associated with the surgical management of ovarian cancer

J. Alejandro Rauh-Hain, MD, MPH^{1,2}, Michael K. Hidrue, PhD³, Peter Gaccione, MA⁴, Alexander Melamed, MD, MPH⁴, Larissa A. Meyer, MD, MPH^{1,2}, Nancy L. Keating, MD, MPH⁵, Sharon H. Giordano, MD, MPH², Laurel W. Rice, M.D.⁶, Michael J. Birrer, MD, PhD⁷, and Marcela G. del Carmen, MD, MPH^{3,4}

¹ Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

² Department of Health Services Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

³ Massachusetts General Physicians Organization, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

⁴ Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

⁵ Department of Health Care Policy, Harvard Medical School, and Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts

⁶ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI

⁷ Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama

Abstract

Objective: Identify the major factors that drive standardized cost in providing surgical care for women with ovarian cancer, characterize the magnitude of variation in resource utilization between centers, and to investigate the relationship between resource utilization and quality of care provided.

Corresponding Author: J. Alejandro Rauh-Hain, MD, MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center 1155 Herman Pressler, Unit 1362, Houston, TX 77030-1362, USA, jarauh@mdanderson.org.
Author Contribution

Each author significantly contributed to the critical aspects of this manuscript, and consequently, preparation of this manuscript would not have been possible without the contributions of each author listed.

Disclosure of Interests: The authors declare that there are no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Methods: Retrospective cohort study of hospitals across the United States reporting to the Premier Database who cared for patients with ovarian cancer diagnosed between 2007–2014. The primary outcome was standardized total cost of the index hospitalization. To assess the relationship between hospital standardized costs and patient outcomes, we identified four measures of quality: 1)complications, 2)re-operation, 3)length of stay > 15 days, and 4)unplanned readmission.

Results: The study population included 15,857 patients treated at 226 hospitals. The median standardized cost for hospitalizations was \$13,267(IQR=\$3,342). Reoperation was associated with 49% increase(95% CI=43%–56%), and having minor complication was associated with 10%(95% CI=8%–12%) increase in standardized cost, a moderate complication was associated with 36%(95% CI=33%–38%) increase, and a major complication was associated with 83%(95% CI=76%–89%) increase. The average risk-adjusted hospital standardized costs for hospitals in the highest resource use quartiles was 56% higher than the average hospital costs for hospitals in the lowest quartile (\$10,826 vs. \$16,933). The largest variation was in operating room standardized cost (45.5% of the total variation in operating room cost is explained by differences in hospital practices) and supplies (41.7%).

Conclusions: We identified significant variation in standardized costs among women who underwent surgery for ovarian cancer, operating room and supply costs are the largest drivers of variation.

Keywords

Ovarian cancer; variation in surgical cost; association of surgical cost and patient outcomes

Introduction

The United States spends more than \$3 trillion (18% of the national budget) on healthcare ¹. Annual expenditures for cancer care in particular in the United States are projected to exceed \$170 billion by 2020 ², explained in part by rising costs of cancer-related surgery and post-operative care ³. Analyses of the cost of care are essential to understand the economic burden of particular surgical interventions, identify the drivers for the rising costs of these interventions, and understand, as well as minimize or eliminate, unwanted variation in costs ⁴. The existence of institutions that have high resource utilization and high costs, relative to their peers, represents substantial inefficiency in the healthcare system, particularly if these costs vary independently of patient-related factors or outcomes ⁵.

The rising cost of health care is exerting increasing pressure on the budgets of the government, health care organizations, companies, and individuals. As commercial and public-sector payers seek to improve the efficiency of the health care system, there is a growing need to improve the quality of care delivery and bend the cost curve. Programs such as the National Surgical Quality Improvement Programs (NSQIP) have been instituted to generate data and identify metrics of quality and safety. These initiatives aim at identifying specific cost drivers and efficiencies to improve quality and mitigate the cost of surgical care. This charge is imperative and of critical relevance across all health care delivery spaces, especially academic medical centers, committed to the tripod of clinical care,

research, and education. To the degree that clinical care does not become more affordable and of higher quality, support for education and research will become more challenging to secure, and these two missions, which are integral to the future of health care and medicine face substantial risks. We present a framework using the example of ovarian cancer surgical treatment to identify drivers of cost and metrics of care quality.

Ovarian cancer is associated with the highest case-fatality ratio of all gynecologic cancers. The initial treatment is multimodal and complex, generally including extensive surgical procedures and chemotherapy. Ovarian cancer has a propensity for early peritoneal dissemination and advanced-stage disease at clinical diagnosis, and therefore resource utilization for the initial surgical management of ovarian cancer is high⁶. The severe morbidity associated with the surgical management of patients with ovarian cancer provides a unique opportunity for surgical episode-of-care evaluation. The objective of the present study was to identify the major factors that drive standardized costs in providing surgical care for patients with ovarian cancer and characterize the magnitude of variation in resource utilization among hospitals. Furthermore, we aimed to investigate the relationship between resource utilization and the quality of care provided by hospitals.

Materials and Methods

Data collection

We analyzed data from the Premier database, an all-payer, fee-supported database created to measure resource utilization and quality. This database has been used by the Centers for Medicare & Medicaid Services (CMS) for measurement of hospital quality and has been widely used in previous health outcomes and health economics studies. The database includes complete billing and coding history for more than 45 million hospital inpatient discharges^{7–12}. All data received from hospitals are validated against Premier standards¹³. The present study was granted exempt status by the Institutional Review Board.

We selected patients with a diagnosis of ovarian cancer [International Classification of Diseases, 9th Revision(ICD-9) codes 183.x] who underwent primary surgery that included ovarian resection, hysterectomy, or both¹⁴ between 2007 and 2014. Among the 17,160 patients who underwent surgery, we excluded patients aged <18 years (n=69). We also excluded those treated at 250 hospitals that had fewer than 10 cases (n=987) because the reliability of such estimates is low. We also excluded patients who died during the index admission (n=150) and those discharged to hospice (n=53) from our analyses of cost and prolonged length of stay (LOS) because we could not reliably predict what would have been their cost for an entire admission if the patients had stayed alive or were not transferred to hospice. We included them in the analysis of post-operative complications (except for readmissions). We applied additional restrictions when analyzing certain models. For the cost analysis, we excluded patients with a reported cost of <\$100(n=111) or >\$500,000 (n=3) and patients with a LOS >30 days (n=151) to minimize the impact of outliers. For the analysis of 90-day readmission, we excluded patients admitted after March 2014 (n=534); and for the prolonged LOS analysis we excluded patients admitted after May 2014 (n=145), because the database had complete data for each patient only through the end of June 2014.

Outcome measures

The primary outcome measure was standardized total cost of the index hospitalization. Premier collects data directly from the cost accounting systems at participating hospitals. Hospital cost accounting systems represent the facilities' best efforts to assign direct and indirect clinical expenditures to patients to manage resources and set prices. Costs were not based on the charges, which have little relationship to true underlying resource utilization¹⁵, and included direct (variable) costs of the resource used and indirect costs (a portion of the hospital's fixed costs). Both variable and fixed costs can vary across hospitals for a variety of reasons including differences in local input prices, hospitals' bargaining power, overhead costs, and long-term investments^{5,16}. This makes comparison of resource utilization based on hospital-reported costs difficult. To adjust for this factor, we employed standardized cost as reported by Lagu et al⁵. We first calculated the median cost across hospitals for each item in the database during a given year and set this as the "standardized" unit cost of that item at every hospital. Once standardized costs were assigned at the item level, we summed the costs of all items assigned to each patient to get the total cost of a hospitalization per patient at each hospital. We hereafter refer to "standardized costs" as "costs." All cost figures were inflation adjusted to 2014 dollars.

To assess the relationship between costs and patient outcomes, we identified four measures of quality: 1) post-operative complications, 2) re-operation, 3) prolonged LOS of more than 15 days, and 4) unplanned readmission. We used ICD-9 codes to identify post-operative complications, based on the Clavien classification system¹⁷. The highest Clavien grade represented the severity of the complication for each patient¹⁸. Re-operation was identified if there was a second billing code for use of the operating room (OR). We identified unplanned readmissions to acute care hospitals within 90 days of discharge from the hospital following primary surgery. To define unplanned readmission we followed an algorithm developed by CMS^{19,20}.

We grouped risk adjustment factors into two categories: those that existed before the patient was admitted to the hospital (baseline factors) and those that developed during hospitalization (hospitalization related factors). Baseline factors included age, race, insurance (Medicare, Medicaid, commercial, none), discharge year, comorbidities, major psychiatric illness (schizophrenia, bipolar disorder, major depression)²¹⁻²³, surgical approach (laparotomy vs. laparoscopy), and number of surgical procedures. We used the comorbidity index proposed by Elixhauser et al.²⁴. For number of procedures, a composite score based on the number of surgical procedures each patient underwent was calculated as previously described by Wright et al^{14,25}. We added the number of ovarian cancer-related surgical procedures to baseline factors because we assumed these were primarily driven by the patient's pre-admission condition. Our rationale was that the number of procedures might reflect the patient's preoperative burden of disease and condition. Hospitalization-related factors included hospital teaching status, region, number of beds, re-operation, and post-operative complications.

Both groups of risk adjustment factors (baseline and hospital-related) are potential predictors of standardized costs and patient outcomes. Because we were interested in the drivers of cost and comparing hospitals on the basis of cost and patient outcomes, we included both groups

when analyzing drivers of cost, but included only baseline characteristics when examining (a) cost variation among hospitals, and (b) the association between hospital spending and patient outcomes ²⁶.

Statistical analysis

We estimated several models. However, the general framework for all models is the same. First, since cost and patient outcomes within a given hospital are likely to be similar than those across other hospitals, we used two-level hierarchical framework to account for the clustering of patients within hospital. Second, since the distribution of cost was right skewed, we specified a gamma distribution with long link to account for the nonnormal distribution of cost. Within this general framework, we estimated three set of models.

The first set of models were designed to identify drivers of cost. We estimated two models: one that adjusted for baseline factors only and one that adjusts for baseline and hospital level factors. The second set of models were designed to measure variation in resource utilization across hospitals. For these models, we adjusted only for baseline factors i.e., factors that were potentially outside the control of hospitals' decisions. Since variation in total cost may hide variation in individual cost categories, we estimated a model for total cost as well as for each of the five cost categories in the Premier dataset: room and board, pharmacy, supplies, OR, and others ^{8–12}.

To quantify variation in costs across hospitals, we calculated the intraclass correlation coefficient (ICC), which measures the proportion of total variance explained by hospitals ²⁷. We also reported the average reliability index. This index provides a measure of accuracy of estimated variation to distinguish true differences from random variation. In general, a reliability index below 0.7 is considered unreliable ²⁸.

The third set of models were designed to assess whether high cost hospitals deliver better patient outcomes. First, to minimize endogeneity bias (i.e., poor patients outcomes leading to higher costs), we dived the data into two time periods: 2007–2010 and 2011–2014. We used data from the first period to estimate hospital-level costs and data from the second period to evaluate the association of hospital-level costs and patient outcomes ²⁹. Risk-adjusted hospital cost is a hospital level average cost that accounts for potential risk factors and differences in sample size. We followed the CMS approach in calculating the average risk-adjusted hospital cost ²⁶. We considered four measures of patient outcome: unplanned admission within 90 days of discharge as defined by an algorithm developed by CMS ^{20,30}], prolonged LOS, re-operation, and postoperative complications. To test the association between hospital cost and patient outcome, we regressed patient outcome on patient characteristics and risk-adjusted hospital cost.

All statistical tests were two-sided and P-values of <0.05 were considered statistically significant. Regression results are reported as odds ratios or rate ratios depending on the outcome variable. All analyses were conducted using SAS, version 9.4(SAS Institute, Inc, Cary, NC).

Results

The study population included 15,857 patients treated at 226 hospitals. The median hospital had 384 beds (Interquartile Range [IQR]=237) and performed 41 surgeries (IQR=79) for ovarian cancer during the period studied. Forty-seven percent of the hospitals had data for all study years. The median age of patients was 59 years (IQR=18), 83.9% of patients had a laparotomy and 17.6% had more than one procedure. The median cost for hospitalizations was \$13,591 (IQR=\$3,342). Overall, 14.9% of patients were re-hospitalized within 90 days, 5.3% were hospitalized for >15 days, 5.4% had a re-operation, and 62.2% experienced some degree of complication (Table 1).

Table 2 presents the adjusted associations of baseline factors and hospitalization-related factors with total costs for the hospitalization. The largest drivers of costs were surgical approach, number of procedures, re-operation, and complications. Laparotomy was associated with a 29% increase in costs (95% confidence interval [CI]=25%–33%), re-operation was associated with a 49% increase (95%CI=43%–56%), and one or more procedure was associated with 29% to 49% increase. Relative to no complications, minor complications were associated with a 10% increase in costs (95%CI=8%–12%), moderate complications were associated with a 36% increase (95%CI=33%–38%), and major complications were associated with an 83% increase (95%CI=76%–89%). Age, black race, Medicaid and Medicare insurance, psychiatric illness, and preoperative comorbidities were also associated with increased hospitalization costs, but the impact was relatively small compared with the above-mentioned factors. Hospital characteristics such as region, teaching status, setting, and number of beds were not significantly associated with costs.

We found notable variation in risk-adjusted hospital costs among hospitals (Table 1 and Appendix Figure 1). The average risk-adjusted hospital costs for hospitals in the highest cost quartile were 56% higher than the average hospital costs for hospitals in the lowest quartile (\$10,826 compared with \$16,933). We did not observe significant differences in cost by teaching status, region, setting, hospital size, or number of patients treated between hospitals in the lower cost quartiles and hospitals in the higher cost quartiles. After adjusting for baseline patient characteristics, we found that 18% of the remaining variation in total costs was attributable to hospitals (Table 3). The average reliability index for this model was 0.89, indicating that most of the observed variation among hospitals was due to real difference rather than random variations.

We found more variation across hospitals by cost category than we did for total costs (Table 3). The largest variation was in OR costs (45.5% of the total variation in OR costs was explained by differences in hospital practices) and supplies (41.7%). There was also variation among hospitals in pharmacy (23.2%) and room and board costs (20.8%).

OR costs were also the fastest growing component of total costs. Over the 8 years studied, OR costs increased by 3.1% (95%CI=2.3–3.9) annually (Table 3). Pharmacy costs, in contrast, declined by 4.2% (95%CI=–5.4% to –2.9%) annually. Because costs were adjusted for annual inflation, these changes represent real changes in resource utilization rates. There was no statistically significant change in total costs over the period studied.

We found that high hospital costs in 2007–2010 were associated with major complications, reoperations, and prolonged LOS in 2011–2014 (Figures 1A–1C). Higher hospital costs were not associated with re-admissions (Figure 1D). In a hierarchical regression model adjusting for pre-admission characteristics, we found that every \$1,000 increase in hospital costs was associated with a 17% increase (95%CI=10%–24%) in prolonged LOS rate, an 18% increase (95%CI= 7%–30%) in the re-operation rate, and an 8% increase (95%CI= 5%–10%) in the complication rate (Table 4).

Discussion

Understanding the drivers of variation in the costs of ovarian cancer care and which components are contributing to rising costs is important in planning and setting priorities for allocating resources. Among women with newly diagnosed ovarian cancer, approximately 40% of the costs of first-line treatment are related to surgery and postoperative care³¹. In the present study of 226 hospitals providing primary ovarian cancer surgery, we found that standardized costs, as a measure of resource utilization, varied substantially across hospitals, even after accounting for important patient and hospital characteristics. Unexplained variation in costs across hospitals was particularly high for OR use and supplies. Additionally, we found a significant association between high costs and lower quality of care. These findings raise important questions about the quality and consistency of care and are an important starting point for quality improvement and service development.

Standard methods of healthcare cost estimation have important limitations, and before determining the reasons for the observed variation, it is important to emphasize the importance of cost standardization. Cost measurement using charges or cost-to-charge ratios estimates only the total costs, and not the marginal costs of services, and this method ignores cost shifting that occurs regularly in hospital accounting³². Additionally, hospital-reported costs are not useful for comparing resource utilization across hospitals because costs reported by hospitals for a treatment or service vary widely across institutions for many reasons, including differences in standard of living, bargaining power, and long-term investments⁵. Thus, to estimate resource utilization and variation across all hospitals, we analyzed standardized costs. Using this approach and adjusting for pre-admission patient factors, we found considerable variation in standardized costs (and thus resource utilization) across hospitals. When we included pre-admission and hospitalization factors in the model, the largest modifiable drivers of hospital standardized costs were reoperation and post-operative complications.

Variation in the use of services has been well documented and may suggest opportunities to reduce unnecessary care³³. Recent studies have linked variations in surgery use to varying payment models, provider preferences, and patient-level factors, and such differences have been associated with variations in post-operative outcomes^{34–36}. Similar to prior studies among patients undergoing surgery³⁷, we also identified substantial variation in risk-adjusted hospital standardized costs. The persistent variation after standardizing costs and adjusting for risk factors closely represents the potentially unwarranted differences in services provided for patients with similar risk and cost profiles. Furthermore, we observed that the largest variation in such costs was in the OR costs and costs of supplies. OR and

supply costs have been shown to comprise large portions of a procedural hospitalization charge³⁸; therefore, surgeons play a crucial role in the cost efficiency of the OR through total operative time, use of supplies, and patient outcomes.

In our study, OR costs increased by almost 3% every year, even after adjusting for inflation, whereas costs in other categories decreased. Although a decrease in LOS from 7 days to 5 days between 2007 and 2014 in our cohort could explain the decrease in costs in categories such as room and board and pharmacy, the reason for the significant increase in OR costs and significant variation across hospitals is unclear. This increase in the rate might have significant implications for hospitals and surgeons. To succeed under current bundled payment models, hospitals and surgeons must collaborate to control both direct and indirect costs. Currently, most early participants in payment bundling are focusing on direct costs, such as expenses related to surgery, inpatient care, post-acute care, and readmissions. The indirect costs associated with increases in OR costs receive less attention. As has been shown in other bundled payment models, considering these indirect costs will be important if cancer-related surgery is included in future oncology models. Further studies are needed to better understand the reasons for rising OR costs and identify effective solutions to contain these costs.

The association between health care quality and costs has been an important consideration in policy debates on whether decreases in health care spending will negatively impact quality or whether quality improvement initiatives will decrease health care spending^{39,40}. The financial realities facing hospitals, including rising costs and lowered reimbursements, make value essential in all surgical procedures. The shift toward coordinated care, risk sharing, bundled payments, and a higher percentage of the patient pool supported by government insurance all necessitate tight cost controls to maintain positive margins⁴¹. In the present study we observed that hospitals with the highest standardized costs for ovarian cancer surgery had poorer quality of care than those with lower standardized costs, as measured by complications, re-operations, and prolonged LOS. Although our results suggest that it may be possible to reduce costs without harming patient outcomes, prior evidence of the direction of association between health care cost and quality is inconsistent. Most studies have found that the association between cost and quality is small to moderate, regardless of whether the direction is positive or negative⁴².

Limitations to the present analysis must be considered. The present study used administrative data for the index hospitalization only, and thus lacked detailed clinical data such as stage, survival, and receipt of neoadjuvant chemotherapy. Additionally, we were unable to measure disease severity across patients in our cohort, so facilities with the most severely ill patients could have had higher average costs and complications. Furthermore, the analysis was limited to a small number of quality indicators, and our risk-adjusted measures of hospital quality may not have sufficiently accounted for more complex patients at some hospitals. Differences among hospitals in the selected quality measures could be attributed to unmeasured confounders (e.g., specialty of the primary surgeon) and selection bias. Lastly, in analyses of quality, we used 2007–2010 hospital costs as a proxy for 2011–2014 hospital costs. This implicitly assumed hospital costs have remained largely the same over the two

periods. Nevertheless, risk-adjusted hospital costs for the two periods were strongly correlated (0.7).

In conclusion, we identified significant variation in standardized costs for ovarian cancer surgery among hospitals, and OR and supply costs were the largest drivers of variation. These findings suggest some opportunities to improve resource utilization in high-cost facilities. In addition, we observed that efforts to decrease reoperations and post-operative complications might have a significant impact on cost reduction. Quality of care initiatives could be used to target care deficiencies in lower-performing facilities to improve the efficiency of care and ultimately potentially decrease costs. Finally, a better understanding of the source of the increasing OR costs could provide an effective target to try to contain the cost of care in this population.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This work is supported by K08CA234333, P30CA016672 and R25CA092203 from the National Cancer Institute at the National Institutes of Health and by the American Association of Obstetrics and Gynecology Foundation.

References

1. Martin AB, Hartman M, Benson J, Catlin A. National health spending in 2014: Faster growth driven by coverage expansion and prescription drug spending. *Health Aff.* 2016;35(1):150–160. doi: 10.1377/hlthaff.2015.1194
2. Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. *J Natl Cancer Inst.* 2011;103(2):117–128. doi:10.1093/jnci/djq495 [PubMed: 21228314]
3. Ho V, Short MN, Aloia TA. Can postoperative process of care utilization or complication rates explain the volume-cost relationship for cancer surgery? *Surg (United States)*. 2017;162(2):418–428. doi:10.1016/j.surg.2017.03.004
4. Ejaz A, Kim Y, Spolverato G, Taylor R, Hundt J, Pawlik TM. Understanding drivers of hospital charge variation for episodes of care among patients undergoing hepatopancreatobiliary surgery. *HPB*. 2015;17(11):955–963. doi:10.1111/hpb.12452 [PubMed: 26256003]
5. Lagu T, Krumholz HM, Dharmarajan K, et al. Spending more, doing more, or both? An alternative method for quantifying utilization during hospitalizations. *J Hosp Med*. 2013;8(7):373–379. doi: 10.1002/jhm.2046 [PubMed: 23757115]
6. Sfakianos GP, Havrilesky LJ. A review of cost-effectiveness studies in ovarian cancer. *Cancer Control*. 2011;18(1):59–64. [PubMed: 21273981]
7. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. *JAMA*. 2010;303(23):2359–2367. doi:10.1001/jama.2010.796 [PubMed: 20551406]
8. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. *JAMA*. 2010;303(20):2035–2042. doi:10.1001/jama.2010.672 [PubMed: 20501925]
9. Schiavone MB, Herzog TJ, Ananth C V., et al. Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. *Am J Obstet Gynecol*. 2012;207(5). doi:10.1016/j.ajog.2012.09.014

10. Stulberg JJ, Delaney CP, Neuhauser D V, Aron DC, Fu P, Koroukian SM. Adherence to surgical care improvement project measures and the association with postoperative infections. *JAMA*. 2010;303(24):2479–2485. doi:10.1001/jama.2010.841 [PubMed: 20571014]
11. David G, Gunnarsson CL, Waters HC, Horblyuk R, Kaplan HS. Economic measurement of medical errors using a hospital claims database. *Value Heal*. 2013;16(2):305–310. doi:10.1016/j.jval.2012.11.010
12. Kim MH, Klingman D, Lin J, Pathak P, Battleman D. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. *Ann Pharmacother*. 2009;43(5):840–848. doi:10.1345/aph.1L698 [PubMed: 19417111]
13. Pasquali SK, Sun J-L, d'Almada P, et al. Center variation in hospital costs for patients undergoing congenital heart surgery. *Circ Cardiovasc Qual Outcomes*. 2011;4(3):306–312. doi:10.1161/CIRCOUTCOMES.110.958959 [PubMed: 21505154]
14. Wright JD, Hou JY, Burke WM, et al. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. *Obstet Gynecol*. 2016;127(6):985–991. doi:10.1097/AOG.0000000000001436 [PubMed: 27159764]
15. Reinhardt UE. The pricing of U.S. hospital services: Chaos behind a veil of secrecy. In: *Health Affairs*. Vol 25;2006:57–59. doi:10.1377/hlthaff.25.1.57 [PubMed: 16403745]
16. Tompkins CP, Altman SH, Eilat E. The precarious pricing system for hospital services. In: *Health Affairs*. Vol 25;2006:45–56. doi:10.1377/hlthaff.25.1.45 [PubMed: 16403744]
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 2004;240(2):205–213. doi:10.1097/01.sla.0000133083.54934.ae [PubMed: 15273542]
18. Chung BI, Leow JJ, Gelpi-Hammerschmidt F, et al. Racial disparities in postoperative complications after radical nephrectomy: A population-based analysis. *Urology*. 2015;85(6):1411–1416. doi:10.1016/j.urology.2015.03.001 [PubMed: 25881864]
19. Horwitz LI, Partovian C, Lin Z, et al. Development and use of an administrative claims measure for profiling hospital-wide performance on 30-day unplanned readmission. *Ann Intern Med*. 2014;161:S66–S75. doi:10.7326/M13-3000 [PubMed: 25402406]
20. Ellimootil C, Khouri R, Dhir A, Hou H, Miller D, Dupree J. An Opportunity to Improve Medicare's Planned Readmissions Measure. *J Hosp Med*. 2017;12(10):840–842. doi:10.12788/jhm.2833 [PubMed: 28991951]
21. Kartha A, Anthony D, Manasseh CS, et al. Depression is a risk factor for rehospitalization in medical inpatients. *Prim Care Companion J Clin Psychiatry*. 2007;9(4):256–262. doi:10.4088/PCC.v09n0401 [PubMed: 17934548]
22. Fingar K, Washington R. Trends in Hospital Readmissions for Four High-Volume Conditions, 2009–2013: Statistical Brief #196. *HCUP Stat Br* #196. 2006:1–17.
23. Correll CU, Ng-Mak DS, Stafkey-Mailey D, Farrelly E, Rajagopalan K, Loebel A. Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: A real-world analysis. *Ann Gen Psychiatry*. 2017;16(1). doi:10.1186/s12991-017-0133-7
24. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity Measures for Use with Administrative Data. *Med Care*. 1998;36(1):8–27. doi:10.1097/00005650-199801000-00004 [PubMed: 9431328]
25. Patankar S, Burke WM, Hou JY, et al. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. *Gynecol Oncol*. 2015;138(1):62–69. doi:10.1016/j.ygyno.2015.04.037 [PubMed: 25976399]
26. Ash AS, Fienberg SE, Louis TA, Normand ST. Statistical Issues In Assessing Hospital Performance. In: *Committee of Presidents of Statistical Societies*;2012:1–63. doi:10.1017/CBO9781107415324.004
27. Watson PF, Petrie A. Method agreement analysis: A review of correct methodology. *Theriogenology*. 2010;73(9):1167–1179. doi:10.1016/j.theriogenology.2010.01.003 [PubMed: 20138353]
28. Adams JL, Mehrotra A, Thomas JW, McGlynn EA. Physician Cost Profiling — Reliability and Risk of Misclassification. *N Engl J Med*. 2010;362(11):1014–1021. doi:10.1056/NEJMsa0906323 [PubMed: 20237347]

29. Tsugawa Y, Jha AK, Newhouse JP, Zaslavsky AM, Jena AB. Variation in physician spending and association with patient outcomes. *JAMA Intern Med.* 2017;177(5):675–682. doi:10.1001/jamainternmed.2017.0059 [PubMed: 28288254]
30. Horwitz LI, Partovian C, Lin Z, et al. Development and use of an administrative claims measure for profiling hospital-wide performance on 30-day unplanned readmission. *Ann Intern Med.* 2014. doi:10.7326/M13-3000
31. Urban RR, He H, Alfonso-Cristancho R, Hardesty MM, Goff BA. The Cost of Initial Care for Medicare Patients With Advanced Ovarian Cancer. *J Natl Compr Canc Netw.* 2016;14(4):429–437. [PubMed: 27059191]
32. Levit KR, Friedman B, Wong HS. Estimating inpatient hospital prices from state administrative data and hospital financial reports. *Health Serv Res.* 2013;48(5):1779–1797. doi: 10.1111/1475-6773.12065 [PubMed: 23662642]
33. Newhouse JP, Garber AM. Geographic Variation in Medicare Services. *N Engl J Med.* 2013;368(16):1465–1468. doi:10.1056/NEJMp1302981 [PubMed: 23520983]
34. Hussey PS, Huckfeldt P, Hirshman S, Mehrotra A. Hospital and regional variation in medicare payment for inpatient episodes of care. *JAMA Intern Med.* 2015;175(6):1056–1057. doi:10.1001/jamainternmed.2015.0674 [PubMed: 25867180]
35. Grenda TR, Pradarelli JC, Thumma JR, Dimick JB. Variation in Hospital Episode costs with bariatric surgery. *JAMA Surg.* 2015;150(12):1109–1115. doi:10.1001/jamasurg.2015.2394 [PubMed: 26376433]
36. Hussey PS, Wertheimer S, Mehrotra A. The association between health care quality and cost a systematic review. *Ann Intern Med.* 2013;158(1):27–33. doi: 10.7326/0003-4819-158-1-201301010-00006 [PubMed: 23277898]
37. Bach PB. A Map to Bad Policy — Hospital Efficiency Measures in the Dartmouth Atlas. *N Engl J Med.* 2010;362(7):569–574. doi:10.1056/NEJMp0909947
38. Stey AM, Brook RH, Needleman J, et al. Hospital costs by cost center of inpatient hospitalization for medicare patients undergoing major abdominal surgery. *J Am Coll Surg.* 2015. doi:10.1016/j.jamcollsurg.2014.10.021
39. Skinner J, Chandra A, Goodman D, Fisher ES. The elusive connection between health care spending and quality. *Health Aff.* 2009;28(1). doi:10.1377/hlthaff.28.1.w119
40. Jha AK, Orav EJ, Dobson A, Book RA, Epstein AM. Measuring efficiency: the association of hospital costs and quality of care. *Health Aff (Millwood).* 2009;28(3):897–906. doi:10.1377/hlthaff.28.3.897 [PubMed: 19414903]
41. Gitelis M, Vigneswaran Y, Ujiki MB, et al. Educating surgeons on intraoperative disposable supply costs during laparoscopic cholecystectomy: A regional health system's experience. *Am J Surg.* 2015. doi:10.1016/j.amjsurg.2014.09.023
42. Hussey PS, Wertheimer S, Mehrotra A. The association between health care quality and cost a systematic review. *Ann Intern Med.* 2013. doi:10.7326/0003-4819-158-1-201301010-00006

Highlights:

- We identified significant variation in resource utilization among hospitals who treat women for ovarian cancer.
- Operating room and supply costs are the largest drivers of variation.
- Operating room costs were the fastest growing component of total costs.
- We found a significant association between high costs and lower quality of care.

Figure 1.
Association of Adjusted Hospital Standardized Costs and Quality Measures.

Table 1:**Hospital and Patient Characteristics by Quartiles of Hospital Standardized Cost**

Covariate	Full Sample	Risk-Adjusted Hospital Cost Quartiles (Lowest to Highest)				
		Q1	Q2	Q3	Q4	P-Value *
Hospital characteristics						
Median adjusted spending	\$13,591	\$10,826	\$12,541	\$14,072	\$16,933	
Number of hospitals	226	56	57	57	56	
Teaching hospitals	43.8%	44.6%	35.1%	52.6%	42.9%	0.6
Urban hospitals	91.6%	83.9%	96.5%	94.7%	91.1%	0.2
Median number of beds	384	352	409	382	422	0.3
Median number of patients	41	37	36	40	53	0.3
Patient characteristics						
Number of patients	15,857	3,691	3,953	3,573	4,640	
Median age (Years)	59	60	59	59	59.0	0.2
Race						
Non-Hispanic white	69.9%	76.2%	72.3%	66.9%	65.1%	<0.001
None-Hispanic black	8.4%	7.4%	9.2%	9.8%	7.3%	0.8
Hispanic	2.80%	0.41%	3.1%	2.7%	4.5%	<0.001
Other	19.0%	16.1%	15.4%	20.6%	23.1%	<0.001
Payer						
Commercial	50.1%	49.3%	48.7%	50.1%	51.8%	0.007
Medicaid	8.4%	8.6%	7.6%	9.0%	8.5%	0.5
Medicare	34.5%	35.9%	34.4%	34.4%	33.5%	0.02
Uninsured	7.0%	6.2%	9.2%	6.5%	6.2%	0.059
Number of Procedures						
0	82.4%	83.4%	86.2%	83.7%	77.5%	<0.001
1	12.0%	11.2%	10.3%	12.0%	13.9%	<0.001
2	4.1%	4.1%	2.8%	3.3%	6.0%	<0.001
3	1.5%	1.3%	0.7%	1.0%	2.7%	<0.001
Median Elixhauser score	2.0	2.0	2.0	2.0	3.0	<0.001
Laparotomy	83.9%	84.8%	84.6%	85.4%	81.6%	<0.001
Median surgery time in minutes	197	180	180	210	223	<0.001
Psychiatric Illness	5.3%	6.1%	4.6%	4.8%	5.6%	0.6
Patient outcomes						
90 day readmission	14.9%	13.0%	13.1%	15.6%	17.5%	<0.001
Prolonged length of stay	5.3%	2.6%	3.3%	4.8%	9.6%	<0.001
Re-operation	5.4%	4.8%	3.6%	5.3%	7.6%	<0.001
Complications						
No complication	37.8%	42.8%	41.6%	36.2%	31.7%	<0.001

Covariate	Full Sample	Risk-Adjusted Hospital Cost Quartiles (Lowest to Highest)				
		Q1	Q2	Q3	Q4	P-Value *
Minor complication	15.2%	16.4%	14.8%	15.1%	14.7%	0.07
Moderate complication	30.5%	28.8%	29.1%	32.4%	31.6%	<0.001
Major complication	15.6%	11.4%	13.5%	15.3%	20.8%	<0.001
Death	0.95%	0.62%	0.96%	1.1%	1.1%	0.02

* The P-values are for tests for trends across the four quartiles. For binary variables, we used the Armitage test, and for continuous variables, we used the Jonckheere-Terpstra test.

Table 2:

Patient and Hospital Factors Associated with an Increased Standardized Cost of Hospitalization

Predictor	Adjusting for Baseline Factors Only		Adjusting for Baseline and Hospital Related Factors	
Predictor	Rate Ratio *	(95% CI)	Rate Ratio *	(95% CI)
Patient age (in decades)	1.02	(1.01 – 1.02)	1.01	(1.01 – 1.01)
Race (ref=white)				
Black	1.07	(1.04 – 1.10)	1.03	(1.01 – 1.05)
Hispanic	1.00	(0.94 – 1.07)	1.00	(0.94 – 1.06)
Other	1.01	(0.98 – 1.04)	1.00	(0.98 – 1.03)
Payer (ref=commercial)				
Medicaid	1.07	(1.03 – 1.10)	1.06	(1.03 – 1.08)
Medicare	1.03	(1.01 – 1.05)	1.03	(1.00 – 1.03)
Uninsured	1.08	(1.05 – 1.11)	1.05	(1.03 – 1.08)
Psychiatric illness	1.05	(1.02 – 1.09)	1.04	(1.01 – 1.07)
Laparotomy	1.44	(1.39 – 1.49)	1.29	(1.25 – 1.33)
Elixhauser score	1.13	(1.12 – 1.14)	1.07	(1.06 – 1.07)
Number of procedures (ref=0)				
1	1.41	(1.37 – 1.45)	1.29	(1.26 – 1.32)
2	1.63	(1.55 – 1.71)	1.42	(1.37 – 1.47)
>=3	1.69	(1.56 – 1.83)	1.49	(1.40 – 1.57)
Secular Trend [†]	0.99	(0.99 – 1.00)	1.00	(0.99 – 1.01)
Re-operation			1.49	(1.43 – 1.56)
Complication (ref=none)				
Minor			1.10	(1.08 – 1.12)
Moderate			1.36	(1.33 – 1.38)
Major			1.83	(1.76 – 1.89)
Teaching hospital			0.99	(0.94 – 1.05)
Rural hospital			0.96	(0.86 – 1.07)
Number of beds			1.00	(0.98 – 1.02)
Region (ref=South Atlantic)				
East North Central			1.02	(0.93 – 1.11)
East South Central			1.00	(0.90 – 1.11)
Middle Atlantic			1.01	(0.93 – 1.10)
Mountain			0.95	(0.83 – 1.09)
New England			1.07	(0.96 – 1.19)
Pacific			1.03	(0.95 – 1.11)
West North Central			0.95	(0.82 – 1.10)
West South Central			0.99	(0.92 – 1.07)

* Rate ratios presented here are estimated from a hierarchical model with log link and gamma distribution.

CI = confidence interval. Ref = reference.

[†]The secular trend was specified as a continuous variable with a value of 1 for 2007 and 8 for 2014.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3:

Proportion of Variation in Hospitalization Cost Explained by Hospitals and Annual Growth of Hospitalization Cost over the Study Period (2007–2014)

Cost Category	Proportion of Variation Explained by Hospitals [*]	Reliability Index ^{**}	Annual Growth in Costs % (95% CI) [†]
Total costs	18.3	0.89	−0.2 (−0.9, 0.5)
Cost Categories:			
Operating room	45.5	0.96	3.1 (2.3, 3.9)
Pharmacy	23.2	0.91	−4.2 (−5.4, −2.9)
Supply	41.7	0.95	−0.5 (−2.6, 1.6)
Room and board	20.8	0.89	−1.2 (−2.2, −0.2)
Other [‡]	24.4	0.91	−1.5 (−2.6, −0.5)

^{*} Proportion of variance explained by hospitals was measured using Intra Class Correlation Coefficient (ICC). The ICC measures the proportion of total variance in the outcome variable explained by differences in hospitals after adjusting for baseline factors. Since variation in total cost can hide variation in individual cost categories, we estimated variation in total cost as well as in the five cost categories by estimating separate model for each cost category.

^{**} Reliability index provides a measure of the accuracy of the estimated variation due to hospitals. In general, a reliability index of greater than 0.7 is considered as reliable²⁸.

[†] Annual growth in hospital cost is measured using the coefficient for secular trend included in the model. Secular trend was specified as a continuous variable with a value of 1 for 2007 and 8 for 2014.

[‡] Other costs included laboratory analyses, electrocardiograms, radiological studies, respiratory studies and therapy, therapy, labor, Emergency Room use, and other miscellaneous costs.

CI = confidence interval.

Table 4:

Association Between Adjusted Hospital Standardized Cost (in \$1,000) ^{*} and Patient Outcomes

Outcome	Odds Ratio	
	Mean	(95% CI)
90 day readmission rate	1.03	(0.99 – 1.07)
Extended length of stay (>15 days)	1.17	(1.10 – 1.24)
Re-operation	1.18	(1.07 – 1.30)
Complication	1.08	(1.05 – 1.10)

^{*} For every \$1,000 increase in adjusted hospital standardized cost.

CI = confidence interval.